RXRX ▼ -5.7% - Recursion Pharmaceuticals, Inc.
$RXRX - New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps
02-NOV-2026 04:25 PM ET
Share this post
More filings for $RXRX
RXRX ▼ -5.0% - Recursion Pharmaceuticals, Inc.Nov 2, 2026RXRX ▼ -5.5% - Recursion Pharmaceuticals, Inc.Nov 2, 2026RXRX ▼ -5.5% - Recursion Pharmaceuticals, Inc.Nov 2, 2026RXRX ▲ +3.0% - Recursion Pharmaceuticals, Inc.Oct 26, 2026RXRX ▲ +0.3% - Recursion Pharmaceuticals, Inc.Oct 15, 2026RXRX ▼ -4.0% - Recursion Pharmaceuticals, Inc.Oct 15, 2026
View full $RXRX filing history →💬 Comments
Loading comments…
Leave a comment